Boehringer-Ingelheim Pharmaceuticals

Boehringer-Ingelheim Pharmaceuticals is a pharmaceutical Compagnie German.

In connection with Boehringer Ingelheim France

The markets for Boehringer Ingelheim France are France and the the Maghreb. Boehringer Ingelheim is a company with family capital. The site of Rheims is the second production site world of Médicament S of the group. The site is specialized in the production of Comprimé S, of liquids of large volumes and of Aérosol S. Blanquefort, in Bordeaux region, ensures the production of made up of fine Chimie, in particular of organic salts, Monomère S, and an active ingredient for Boehringer Ingelheim.

History

1885 Albert Boehringer buys a small chemical plant with Ingelheim. One carries out it the tartaric manufacture of Acid.
1895 Creation of the first logo of the company.
1912 Launching of the first medicinal product: LAUDANON ® (Analgesic).
1927 Heinrich Otto Wieland, researcher at Boehringer, was seen decreeing the Nobel Prize for its research on the composition of the biliary Acid and the close substances .
1941 Launching of ALUDRIN ® treatment against the Asthma.
2000 Launching of Micardis®
2002 Launching of Spiriva® against BPCO
2003 Recording of Respimat® Atomizer

Logo

The logo of Boehringer Ingelheim is a turn of Charlemagne in Ingelheim, which wants to be a symbol for a European company . Is an interpretation of the central part of the imperial palace of Charlemagne. The king of the Francs, crowned Emperor, remained in Ingelheim during the end of the 8th century, probably towards 774.

Today

Boehringer Ingelheim is an international group with 144 subsidiary companies in 45 countries, and with the 15th rank of the leaders of the drug company present everywhere in the world.

Boehringer Ingelheim is classified with the eleventh world rank of the sector of family medication, but with the eighth rank in France.

Key figures

Its world turnover, in 2005, rises to 10 billion euros.

Directed towards research

Boehringer Ingelheim invests 16% of its turnover for a budget of Recherche and development. France is an engine on all the levels and the clinical research. The company has one of the most important structures of clinical research of the group, in France. This team includes/understands a hundred people. The basic research of the group is distributed on 5 sites:

Therapeutic fields

Boehringer Ingelheim has five branches of activity: Animal health, Biotechnologies, family Medication, Chemistry and Regulation/Hospital. The therapeutic fields are:

Respiratory
Cardiovascular
central Nervous system
Virology
Urology
Immunology
Oncology

Products of pharmacy

Actilyse® with Alteplase against the Myocardial infarction and the cerebral vascular accidents (see also Thrombolyse)
Alna® for the therapy of the diseases of Prostate
Berodual® with Ipratropiumbromid + Fenoterol for the Asthma bronchiale
Cymbalta® against the depression
Micardis® with Telmisartan
Mobec® with Meloxicam, a Anti-inflammatory drug not stéroïdien against the Arthritis
Sifrol® with Pramipexol against the Parkinson's disease
Spiriva® with Tiotropium for the therapy of BPCO
Thomapyrin® with Acetylsalicylic acid, Cafeine and Paracetamol.
Viramune® antiviral drugs against HIV

Products of microsystem

The site of Dortmund is responsible for research and manufacture for the Microsystème S in combination with the products for pharmacy for the Respiratory system. Biopuce S are also manufactured there.

Blockbusters

Spiriva, a new treatment of B.I of BPCO (bronchitis of the smokers) have just exceeded the billion American dollars from sales over 12 months, after three years of marketing in the world. It is the first Blockbuster of the group.

Program gifts

The virus HIV, agent responsible for the infection with the HIV (AIDS), striking currently more than 45 million people on a world level, and more particularly in south-Saharan Africa, or the developing countries.

Answering the call to the mobilization of the General secretary of the United Nations Kofi Annan, Boehringer Ingelheim, at the sides of others Laboratory S and agencies U.N., resolutely engaged in favor of the access to the antirétroviraux in the countries of the South, with a programme of gifts and prevention of the transmission mother-child of virus HIV. More than 400.000 couples mother-child were already treated in 55 countries.

Engagement to accompany the training of young people

In close cooperation with:

the group Rheims Management School
the University S of Pharmacy and Medicine
I.U.T
the E.S.I.E.C (packing and conditioning).

Local cultural engagement

Original musical patronage

Musical evenings: annual cycle in 70 concerts bringing together 80 young artists or young traditional formations.

Local actions

Rheims Champagne Development - Invest in Rheims
Stage of Rheims

Valorization of the inheritance

Support for the Friendly of the cathedral of Rheims
Sponsorship of cultural exposures.

Price

The Price Communication Dispensary (PCO®) reward each year creativity of future graduates, thus symbolizing the attachment of Boehringer Ingelheim to all the facets of the exercise of the pharmacist.

Random links: